source
- FDA advisory panel reviews Replimune's experimental melanoma therapy RP1STAT is live-blogging an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting that convened on Thursday to examine Replimune's engineered viral immunotherapy RP1 for melanoma. The p…
- Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases“The next 10 years of mycetoma care will determine whether it remains a story of neglect or becomes one of collective action,” writes Borna Nyaoke-Anoke.